Brand-name drug companies often use clusters of related patents to block generic competitors in court. This bill caps how many related patents can be used in a single lawsuit and bars repeat suits on the same patent group against the same company.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
ETHIC Act is a House bill in committee. The latest recorded action: Referred to the House Committee on the Judiciary.
Latest action on H.R. 3269: Referred to the House Committee on the Judiciary.
Who this affects: This bill primarily affects brand-name drug and biologic companies that hold multiple related patents, as well as generic and biosimilar manufacturers that face patent infringement lawsuits. Consumers could be indirectly affected if changes in patent litigation lead to faster market entry for cheaper drug alternatives.
Why this matters: Drug patent thickets are a major barrier to affordable medications. When brand-name companies can pile on related patents in court, generic manufacturers face enormous legal costs and delays that keep cheaper alternatives off the market. This bill directly addresses that barrier by limiting how patents can be used in these specific lawsuits.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Keep acting on Modern Action
Compare the broader issue and related bills without leaving Modern Action.
